Is NCT06113809 recruiting in Iowa City, IA?

Yes, NCT06113809 is currently recruiting participants at its Iowa City, IA location. This sarcoma clinical trial is actively enrolling qualified participants.

How do I join the sarcoma clinical trial in Iowa City?

To join this clinical trial in Iowa City, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Iowa City clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Sarcoma Clinical Trial in Iowa City, IA

About This Sarcoma Study in Iowa City

This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma).

Sponsor: John Rieth

Who Can Participate

Inclusion Criteria

A potential subject must meet all the following inclusion criteria to be eligible to participate in the study:

Male or female patients aged \> or = 12 years old

ECOG Performance Status of \< or = 2

Any patient with the diagnosis of locally advanced, unresectable or metastatic sarcoma for which PD-1 inhibitors are approved (undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, alveolar soft part sarcoma) who have progressed on at least 1 prior line of therapy. Prior immunotherapy treatment is allowed, including prior treatment with a PD-1 inhibitor.

Patients with no known CNS disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing treatment for dexamethasone (as ascertained by clinical examination and brain imaging) during the screening period. Stable dose of anticonvulsants is allowed. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.

Ability to understand and the willingness to sign a written informed consent or assent in case of patients \< 18 years old.

Exclusion Criteria

A potential subject who meets any of the following exclusion criteria is ineligible to participate in the study:

Lab values in the below ranges:

Neutrophil count \< 1000/mm3

Platelet count \< 100,000/mm3L

Hemoglobin \< 9 g/dL (transfusion to meet eligibility allowed)

AST/SGOT and ALT/SGPT \> 3.0x upper limit of normal (ULN) without disease involvement or \> 5.0x ULN if the transaminase elevation is due to disease involvement

Alkaline phosphatase \> 5.0x ULN without known bony metastases

Serum bilirubin \> 1.5x ULN

Serum creatinine \> 1.5x ULN or 24-hour creatinine clearance \< 30 mL/min per Cockroft- Gault equation

Total serum calcium \< lower limit of normal (LLN) or if calcium is below LLN the corrected calcium for serum albumin is \> LLN

Serum potassium \< 3.0

Serum sodium \< 130

Serum albumin \< 2.5 g/dL

History of myocardial infarction. unstable angina, stroke or transient ischemic attack within 6 months prior to Day 1

History or drug induced pneumonitis (both pembrolizumab and palbociclib can cause pneumonitis)

Subjects requiring hemodialysis

Patients with severe hepatic impairment (Childs-Pugh Class C).

Other concurrent severe and/or uncontrolled medical conditions in the opinion of the investigator which will preclude participation

Pregnancy (positive pregnancy test) or lactation

Concomitant use of any other anti-cancer therapy or radiation therapy of the target lesion. Palliative radiation therapy is permitted to non-target lesions.

Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT06113809) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sarcoma Treatment Options in Iowa City, IA

If you're searching for sarcoma treatment options in Iowa City, IA, this clinical trial (NCT06113809) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced sarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sarcoma clinical trials near you to find additional studies recruiting in your area.

Sarcoma Clinical Trial in Iowa City, IA

Expert Care in Iowa City

IRB Approved

No-Cost Care

Apply for This Iowa City Location

Why Participate?

Simple Process